{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:02:27Z","timestamp":1793782947085,"version":"4.6.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1\/3 (MASP1\/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p &amp;lt; 0.001), and interstitial fibrosis (43% vs. 13%, p &amp;lt; 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p &amp;lt; 0.001) is a risk factor in LN. MBL, MASP1\/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>TMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1081942","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T06:46:32Z","timestamp":1670913992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation"],"prefix":"10.3389","volume":"13","author":[{"given":"Binshan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.141","article-title":"B-cell depletion in the treatment of lupus nephritis","volume":"8","author":"Gregersen","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study","author":"Tian","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0401-9","article-title":"Protecting the kidney in systemic lupus erythematosus: From diagnosis to therapy","volume":"16","author":"Maria","year":"2020","journal-title":"Nat Rev Rheum"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1681\/asn.V481499","article-title":"Renal vascular complications of systemic lupus erythematosus","volume":"4","author":"Appel","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.409","article-title":"Inclusion of renal vascular lesions in the 2003 Isn\/Rps system for classifying lupus nephritis improves renal outcome predictions","volume":"83","author":"Wu","year":"2013","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2013010026","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1202588109","article-title":"Revised mechanism of complement lectin-pathway activation revealing the role of serine protease masp-1 as the exclusive activator of masp-2","volume":"109","author":"H\u00e9ja","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1053\/j.ackd.2019.10.003","article-title":"Complement and the kidney: An overview","volume":"27","author":"Thurman","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/srep31877","article-title":"Masp-3 is the exclusive pro-factor d activator in resting blood: The lectin and the alternative complement pathways are fundamentally linked","volume":"6","author":"Dob\u00f3","year":"2016","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501717","article-title":"Masp-1 and masp-2 do not activate pro-factor d in resting human blood, whereas masp-3 is a potential activator: Kinetic analysis involving specific masp-1 and masp-2 inhibitors","volume":"196","author":"Oroszl\u00e1n","year":"2016","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.06230614","article-title":"Molecules great and small: The complement system","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2022.03.005","article-title":"Intertwined pathways of complement activation command the pathogenesis of lupus nephritis","volume":"245","author":"Satyam","year":"2022","journal-title":"Transl Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.04.030","article-title":"Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients","volume":"74","author":"Nisihara","year":"2013","journal-title":"Hum Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-011-1361-6","article-title":"The association between the mannose-binding lectin codon 54 polymorphism and systemic lupus erythematosus: A meta-analysis update","volume":"39","author":"Lee","year":"2012","journal-title":"Mol Biol Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cei.13497","article-title":"Masp2 levels are elevated in thrombotic microangiopathies: Association with microvascular endothelial cell injury and suppression by anti-Masp2 antibody narsoplimab","volume":"203","author":"Elhadad","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00371.x","article-title":"Effects of complement factor d deficiency on the renal disease of Mrl\/Lpr mice","volume":"65","author":"Elliott","year":"2004","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.195","article-title":"Stec-hus, atypical hus and ttp are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"European League against Rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the international society of Nephrology\/Renal pathology society classification for lupus nephritis: Clarification of definitions, and modified national institutes of health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the sledai. a disease activity index for lupus patients. the committee on prognosis studies in sle","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/0886022x.2019.1702057","article-title":"Renal microvascular lesions in lupus nephritis","volume":"42","author":"Ding","year":"2020","journal-title":"Ren Fail"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"Clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200104053441406","article-title":"Complement. first of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180773","article-title":"Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy","volume":"46","author":"Li","year":"2019","journal-title":"J Rheum"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199709000-00003","article-title":"Renal vascular lesions in lupus nephritis","volume":"76","author":"Descombes","year":"1997","journal-title":"Med (Baltimore)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90338-8","article-title":"Prognostic factors in lupus nephritis. contribution of renal histologic data","volume":"75","author":"Austin","year":"1983","journal-title":"Am J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2238oa","article-title":"Factors associated with poor outcomes in patients with lupus nephritis","volume":"14","author":"Contreras","year":"2005","journal-title":"Lupus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654652","article-title":"The spectrum of C4d deposition in renal biopsies of lupus nephritis patients","volume":"12","author":"Ding","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.00620117","article-title":"Thrombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310376523","article-title":"Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy","volume":"19","author":"Hu","year":"2010","journal-title":"Lupus"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(12)80885-7","article-title":"Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. gruppo italiano per lo studio Della nefrite lupica (Gisnel)","volume":"18","author":"Banfi","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2005080868","article-title":"Factor h and atypical hemolytic uremic syndrome: Mutations in the c-terminus cause structural changes and defective recognition functions","volume":"17","author":"J\u00f3zsi","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.06.030","article-title":"Are complement deficiencies really rare? overview on prevalence, clinical importance and modern diagnostic approach","volume":"61","author":"Grumach","year":"2014","journal-title":"Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.85","article-title":"Redefining lupus nephritis: Clinical implications of pathophysiologic subtypes","volume":"13","author":"Yu","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103072","article-title":"Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management","volume":"21","author":"Scheen","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05499-1","article-title":"Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis","volume":"40","author":"Mejia-Vilet","year":"2021","journal-title":"Clin Rheum"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141163","article-title":"Levels in plasma of the serine proteases and associated proteins of the lectin pathway are altered in patients with systemic lupus erythematosus","volume":"42","author":"Troldborg","year":"2015","journal-title":"J Rheum"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311415561","article-title":"Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis","volume":"20","author":"Sato","year":"2011","journal-title":"Lupus"},{"key":"B43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1084\/jem.20090633","article-title":"Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor d","volume":"207","author":"Takahashi","year":"2010","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.2.786","article-title":"Modulation of renal disease in Mrl\/Lpr mice genetically deficient in the alternative complement pathway factor b","volume":"164","author":"Watanabe","year":"2000","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2010060647","article-title":"Complement factor h deficiency accelerates development of lupus nephritis","volume":"22","author":"Bao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/0961203311422093","article-title":"Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: A pilot study","volume":"21","author":"Batal","year":"2012","journal-title":"Lupus"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310368409","article-title":"Association between anti-Beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: A prospective study of 155 cases","volume":"19","author":"Shen","year":"2010","journal-title":"Lupus"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2014050429","article-title":"Complement factor C4d is a common denominator in thrombotic microangiopathy","volume":"26","author":"Chua","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061813-013241","article-title":"Adamts13 and Von willebrand factor in thrombotic thrombocytopenic purpura","volume":"66","author":"Zheng","year":"2015","journal-title":"Annu Rev Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-Target in systemic lupus erythematosus: Advancing towards its implementation","volume":"18","author":"Parra S\u00e1nchez","year":"2022","journal-title":"Nat Rev Rheum"},{"key":"B53","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12882-020-01888-5","article-title":"A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy","volume":"21","author":"Wright","year":"2020","journal-title":"BMC Nephrol"},{"key":"B54","article-title":"Eculizumab (Alexion)","volume":"3","author":"Kaplan","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"B55","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of anca-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113433","article-title":"Complement factor b inhibitor Lnp023 improves lupus nephritis in Mrl\/Lpr mice","volume":"153","author":"Chen","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690821","article-title":"Factor d inhibition blocks complement activation induced by mutant factor b associated with atypical hemolytic uremic syndrome and membranoproliferative glomerulonephritis","volume":"12","author":"Aradottir","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1081942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T06:46:34Z","timestamp":1670913994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1081942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2022.1081942"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1081942","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"article-number":"1081942"}}